1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. RemeGen Co., Ltd.
  6. News
  7. Summary
    9995   CNE1000048G6

REMEGEN CO., LTD.

(9995)
  Report
Delayed Hong Kong Stock Exchange  -  04:09 2022-08-05 am EDT
53.50 HKD   +6.68%
08/03RemeGen to Purchase $4.4 Million of Wealth Management Products
MT
07/22RemeGen to Purchase Wealth Management Products from Qingdao Bank for $11.8 Million
MT
07/05RemeGen Invests $14 Million in Wealth Management Products
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

RemeGen Lists in Shanghai's STAR Market

03/31/2022 | 02:40am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
REMEGEN CO., LTD. 6.68% 53.5 Delayed Quote.-31.32%
UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH) 0.12% 6.7598 Delayed Quote.6.21%
All news about REMEGEN CO., LTD.
08/03RemeGen to Purchase $4.4 Million of Wealth Management Products
MT
07/22RemeGen to Purchase Wealth Management Products from Qingdao Bank for $11.8 Million
MT
07/05RemeGen Invests $14 Million in Wealth Management Products
MT
05/05RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Dire..
CI
04/28RemeGen Widens Q1 Loss as R&D, Selling Expenses Balloon
MT
04/27RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/12RemeGen Co., Ltd. Announces Executive Changes
CI
04/11UBS Upgrades RemeGen to Buy From Neutral, Adjusts Price Target to HK$75.03 From HK$108
MT
03/31RemeGen Lists in Shanghai's STAR Market
MT
03/22RemeGen Prices Shanghai IPO to Raise $410 Million
MT
More news
Analyst Recommendations on REMEGEN CO., LTD.
More recommendations
Financials
Sales 2022 950 M 141 M 141 M
Net income 2022 -975 M -144 M -144 M
Net cash 2022 2 396 M 354 M 354 M
P/E ratio 2022 -24,3x
Yield 2022 -
Capitalization 29 710 M 4 394 M 4 394 M
EV / Sales 2022 28,7x
EV / Sales 2023 13,1x
Nbr of Employees 2 121
Free-Float 49,3%
Chart REMEGEN CO., LTD.
Duration : Period :
RemeGen Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REMEGEN CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 46,08 CNY
Average target price 61,91 CNY
Spread / Average Target 34,3%
EPS Revisions
Managers and Directors
Jian Min Fang CEO, Executive Director & Chief Scientific Officer
Dao Tian Fu President
Jia Li Chief Financial Officer & Joint Secretary
Weidong Wang Chairman
Ruyi He Executive Director & Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
REMEGEN CO., LTD.-31.32%4 394
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-19.26%41 093